Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by Caribou Biosciences
Vispacabtagene regedleucel is an allogeneic, off-the-shelf T-lymphocyte therapy engineered to express a chimeric antigen receptor against CD19, with CRISPR editing to remove endogenous T-cell receptor and PD-1 expression. Its CD19-directed T cells are designed to kill CD19-expressing cells, and it is being studied in systemic lupus erythematosus and lupus nephritis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06752876 | Phase 1 | Systemic Lupus Erythematosus | Withdrawn | CRBU |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
LupusLupus ErythematosusLupus NephritisSystemic Lupus Erythematosus
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRBU page.
See CRBU's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRBU catalysts and pipeline →